QIAGEN IPA
Make discoveries from public data (GEO, SRA and more) using QIAGEN Ingenuity Pathway Analysis
240 views
You asked for it, and we’re here to deliver. We are hosting a comprehensive training on effectively using sample-level public data and metadata from sources like GEO, SRA, TCGA, GTEx, Blueprint, CCLE and others through QIAGEN Ingenuity Pathway Analysis (IPA) and the IPA Analysis Match Explorer feature. We’ll walk you through use cases involving biomarker discovery, drug target investigation, studying survival in custom patient cohorts, multi-gene correlation and more.
We’ll cover topics like:
• How is a gene of interest expressed across different conditions?(‘conditions’ refers to diseases, disease subtypes, treatments, cell types, cell lines and more)
• Is there a correlation in expression for two genes or biomarkers of user interest for a given condition?
• Can we compare more than two genes in a heatmap?
• For a given condition of interest, can we derive a list of genes (for example, genes specific to a disease, treatment or cell type)?
• Can we generate custom cohorts of patients (for example, TP53 wt vs. mutant or PDCD1 high vs. low expression) and then create survival curves representing those cohorts? Can we generate a p-value to see if there is a significant difference?
• Can we detect the expression of a gene in different cell types from single-cell data?
Related videos
QIAGEN IPA
Discovery from public data (GEO, SRA and more) using Ingenuity Pathway Analysis
Per user feedback, we are hosting a comprehensive training on how to...
QIAGEN IPA
The epididymis: Balancing the burden and responsibility of fertility
The responsibility of fertility is disproportionately placed on women, who...
QIAGEN IPA
What’s new in QIAGEN IPA Fall Release 2023?
Interested in learning about new features and functionalities that have been...
QIAGEN IPA
Multi-omics (metabolomics, proteomics, transcriptomics) analysis using QIAGEN Ingenuity Pathway...
This 90-minute training session is about how QIAGEN Ingenuity Pathway...